Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Biogen Hits Primary Endpoints in MS Study
Biogen Hits Primary Endpoints in MS Study
Biogen Hits Primary Endpoints in MS Study
Submitted by
admin
on April 6, 2013 - 10:53am
Source:
Motley Fool
News Tags:
Biogen
MS
multiple sclerosis
daclizumab
Headline:
Biogen Hits Primary Endpoints in MS Study
Do Not Allow Advertisers to Use My Personal information
